Peter Miller, MD
Gastroenterology · Montgomery, ALNPI 1215911490
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 316 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 21.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,466 and has fallen 96.2% since, to $55 in 2024.
Across 316 payments — averaging $14.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$984
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$846
- Takeda Pharmaceuticals U.S.A., Inc.$504
- Johnson & Johnson$454
- Pfizer$396
- Ferring Pharmaceuticals Inc.$127
- plus $1K from 23 others
Across 10 payments — averaging $2897.43 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$29K
What the payments were for
- Consulting fees$150%
- Food & beverage$4,652100%
- Education$50%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 68 | $984 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 62 | $846 |
| Takeda Pharmaceuticals U.S.A., Inc. | 38 | $504 |
| Johnson & Johnson | 37 | $454 |
| Pfizer | 25 | $396 |
| Ferring Pharmaceuticals Inc. | 8 | $127 |
| Gilead | 8 | $126 |
| Intercept Pharmaceuticals, Inc. | 8 | $126 |
| Sanofi | 5 | $123 |
| Amgen | 7 | $102 |
| Bristol Myers Squibb | 6 | $97 |
| Merck | 5 | $94 |
| QOL Medical, LLC | 3 | $94 |
| Redhill Biopharma Inc. | 5 | $86 |
| Ardelyx, Inc. | 4 | $86 |
| UCB, Inc. | 5 | $73 |
| Nestle Healthcare Nutrition Inc. | 5 | $62 |
| Ironwood Pharmaceuticals, Inc | 4 | $56 |
| AstraZeneca | 2 | $34 |
| Enterra Medical, Inc. | 1 | $30 |
| Digestive Care, Inc. | 1 | $28 |
| Braintree Laboratories, Inc. | 2 | $27 |
| Daiichi Sankyo Inc. | 1 | $22 |
| Regeneron Healthcare Solutions, Inc. | 1 | $21 |
| Alnylam Pharmaceuticals Inc. | 1 | $21 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Medtronic | 1 | $14 |
| Boston Scientific | 1 | $13 |
| Evoke Pharma, Inc. | 1 | $12 |
How this compares
$4,672 in reported general payments places this provider in the 60th percentile of 225 gastroenterology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Famotidine | 23 | $507 |
| Pantoprazole Sodium | 28 | $433 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Montgomery
- Viplove SenadhiMontgomery$282K
- Paul Vincent CoMontgomery$8K
- Robert ShafferBirmingham$1M
- Jack DipalmaMobile$903K
- Phillip HendersonMobile$462K
- Travis RutlandDothan$302K
- Mukul MehraBirmingham$193K
- William SonnierMobile$178K
- Jorge HerreraMobile$167K
- Meagan GrayBirmingham$113K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.